Amsterdam: The European Medicines Agency has begun reorganising its scientific committees ahead of the entry into force of the EU Pharma Package, the most substantial overhaul of pharmaceutical legislation in more than two decades. The final compromise texts, a regulation and a directive, were published in March after political agreement was reached in December 2025 and confirmed by the Council’s COREPER I configuration. With formal adoption expected this summer, the agency now faces a two-year transition through 2028 to operationalise rules that touch every stage of a medicine’s life cycle, from authorisation to environmental disposal.
The headline change is procedural. EMA’s scientific assessment timeline for new medicines compresses from 210 days to 180 days, a reduction the agency’s leadership has cautiously welcomed while warning of staffing pressures. Sponsors will gain earlier interaction with assessors through a redesigned scientific-advice pathway, and the Committee for Medicinal Products for Human Use will be restructured to integrate paediatric and orphan-drug expertise more tightly into mainline review. The intention is to close the gap between European and US Food and Drug Administration timelines, which has widened steadily since the COVID-19 era and become a recurring complaint of innovator companies considering where to file first.
For Amsterdam, where the agency relocated from London after the United Kingdom’s withdrawal from the Union, the package is also a real-estate and recruitment story. EMA expects to add roughly 220 full-time staff between 2026 and 2028 to absorb the new workload, and its Zuidas headquarters has begun planning for an expanded conference and inspection footprint. Dutch officials, who courted EMA aggressively in 2017, see the expansion as vindication of the host-city case and as a fillip for the broader life-sciences cluster that has formed around the Amsterdam Science Park.
Substantively, the package recalibrates the balance between innovator incentives and patient access. Regulatory data protection, the period during which generic manufacturers cannot rely on the originator’s clinical dossier, is restructured into a modular system. A baseline of seven and a half years can be extended through additional increments tied to supply commitments, unmet medical need, and participation in publicly funded research. The negotiated compromise narrows the most aggressive cuts that Parliament had pushed for in 2023, while still tightening conditions relative to the existing eight-plus-two regime.
Two further provisions deserve close attention. Enhanced supply obligations require that authorised medicines be made available in any member state on request, including engagement with pricing and reimbursement procedures and participation in national procurement processes. The provision attempts to address the entrenched problem of company decisions to withdraw or never launch products in smaller markets, a complaint sharpest in the Baltic states and Bulgaria. Whether the obligation is enforceable in practice will depend on the Commission’s implementing acts, due in 2027.
Environmental sustainability finds a foothold for the first time in the EU pharmaceutical framework. Manufacturing authorisations will incorporate environmental-risk assessments covering antimicrobial-resistance contributions and pharmaceutical residues in waterways. The provision, championed by Swedish and German MEPs, drew sharp resistance from generic manufacturers but survived the trilogue largely intact. The reform’s success will be measured against two yardsticks: whether European patient access actually accelerates relative to the United States, and whether innovator companies continue to choose EU jurisdictions for first filings.
